U.S. FDA declines emergency use approval for Humanigen's COVID-19 drug

Humanigen

09/09/2021 05:27

Sept 9 (Reuters) - The U.S. Food and Drug Administration
declined Humanigen Inc's  HGEN.O  request for emergency use
authorization of its lenzilumab drug to treat newly hospitalized
COVID-19 patients, the company said on Thursday.
    "In its letter, FDA stated that it was unable to conclude
that the known and potential benefits of lenzilumab outweigh the
known and potential risks of its use as a treatment for
COVID-19," the company said in a statement.  urn:newsml:reuters.com:*:nBw1C3Ctqa

 (Reporting by Aakriti Bhalla in Bengaluru; Editing by Shounak
Dasgupta)
 ((Aakriti.Bhalla@thomsonreuters.com))